Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 47.03 - 112.57
Open     -
Vol / Avg. 0.00/601,944.00
Mkt cap 7.75B
P/E     -
Div/yield     -
EPS -5.37
Shares 76.93M
Beta 1.65
Inst. own 78%
Feb 11, 2015
Q4 2014 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 12, 2014
Alnylam Pharmaceuticals Inc R&D Day
Dec 11, 2014
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference
Dec 3, 2014
Alnylam Pharmaceuticals Inc at Piper Jaffray Healthcare Conference
Dec 2, 2014
Alnylam Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 14, 2014
Alnylam Pharmaceuticals Inc Conference Call to discuss the initial Phase 2 results with revusiran (ALN-TTRsc)
Nov 12, 2014
Alnylam Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 6, 2014
Alnylam Pharmaceuticals Inc at Nomura Biotechnology Conference
Nov 5, 2014
Q3 2014 Alnylam Pharmaceuticals Inc Earnings Call
Nov 5, 2014
Q3 2014 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -400.92% -189.17%
Operating margin -411.95% -197.05%
EBITD margin - -175.36%
Return on average assets -17.48% -25.20%
Return on average equity -19.11% -44.13%
Employees 165 -
CDP Score - -


3rd Floor, 300 Third Street
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alnylam Pharmaceuticals, Inc. (Alnylam) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). Its Alnylam 5x15, is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases. Its core programs in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis (ATTR); ALN-APC for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia, and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. In March 2014, the Company acquired Merck's wholly owned subsidiary Sirna Therapeutics, Inc.

Officers and directors

John K. Clarke Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Barry E. Greene President, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 51
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development
Bio & Compensation  - Reuters
Laurence E. Reid Ph.D. Senior Vice President, Chief Business Officer
Age: 50
Bio & Compensation  - Reuters
Michael P. Mason Vice President - Finance, Treasurer
Age: 39
Bio & Compensation  - Reuters
Michael W. Bonney Director
Bio & Compensation  - Reuters
Amy W. Schulman Director
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters